Zusammenfassung
Bei der retroperitonealen Fibrose (RPF, Morbus Ormond) handelt es sich um eine seltene, chronische, entzündlich-fibrosierende Erkrankung des hinteren Bauchraumes. Sie ist gekennzeichnet durch die gutartige Vermehrung von retroperitonealem Weichteilgewebe. In ihrer typischen Lokalisation breitet sich die Fibrose symmetrisch um die Aorta aus, beginnt unterhalb der Nierenstielgefäße und reicht bis unterhalb der Aortenbifurkation. Bei ihrer Ausbreitung erreicht die Fibrose meist als erstes Organ die Ureteren, sodass eine obstruktive Uropathie mit konsekutiver Hydronephrose die häufigste Komplikation dieser Erkrankung ist.
This is a preview of subscription content, log in via an institution.
Literatur
Adler S, Lodermeyer S, Gaa J, Heemann U (2008) Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis. Rheumatology (Oxford) 47(10):1535–1538
Alberici F, Palmisano A et al (2013) Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis 72(9):1584–1586
Armatys SA, Mellon MJ et al (2009) Use of ileum as ureteral replacement in urological reconstruction. J Urol 181(1):177–181
Binder M, Christoph S et al (2012) Elevated serum osteopontin levels in idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol 30(5):772–775
Brandt AS, Kamper L et al (2011) Associated findings and complications of retroperitoneal fibrosis in 204 patients: results of a urological registry. J Urol 185(2):526–531
Brandt AS, Kamper L et al (2013) An aid to decision-making in therapy of retroperitoneal fibrosis: dynamic enhancement analysis of gadolinium MRI. J Clin Med Res 5(1):49–56
Brandt AS, Kamper L, Kukuk S, Haage P, Roth S (2014) Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis. Urol Int. 2014;93(3):320–325
Brandt AS, Kukuk S, Dreger NM, Müller E, Roth S (2015) Therapie der retroperitonealen Fibrose: Funktionelle Behandlungsergebnisse, Urologe A. 2015 Jan;54(1):62–69
Burkhardt Soares S, Fehr A et al (2007) Retroperitoneal fibrosis. Aktuelle Urol 38(3):221–231
Burn PR, Singh S et al (2002) Role of gadolinium-enhanced magnetic resonance imaging in retroperitoneal fibrosis. Can Assoc Radiol J 53(3):168–170
Caiafa RO, Vinuesa AS et al (2013) Retroperitoneal fibrosis: role of imaging in diagnosis and follow-up. Radiographics: Rev Publ Radiol Soc N Am Inc 33(2):535–552
Catanoso MG, Spaggiari L et al (2012) Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol 30(5):776–778
Duchene DA, Winfield HN et al (2007) Multi-institutional survey of laparoscopic ureterolysis for retroperitoneal fibrosis. Urology 69(6):1017–1021
Fry AC, Singh S et al (2008) Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: a retrospective study. Nephron Clin Pract 108(3):c213–c220
Heidenreich A, Derakhshani P et al (2000) Treatment outcomes in primary and secondary retroperitoneal fibrosis. Urologe A 39(2):141–148
Ilie CP, Pemberton RJ et al (2006) Idiopathic retroperitoneal fibrosis: the case for nonsurgical treatment. BJU Int 98(1):137–140
Kamper L, Brandt AS et al (2011) MR evaluation of retroperitoneal fibrosis. RoFo: Fortschr Gebiete Rontgenstrahlen Nuklearmedizin 183(8):721–726
Kamper L, Brandt AS, Ekamp H, Hofer M, Roth S, Haage P, Piroth W (2014) The potential role of modern US in the follow-up of patients with retroperitoneal fibrosis. Diagn Interv Radiol. 2014 Jan-Feb;20(1):3–8
Kardar AH, Kattan S et al (2002) Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration. J Urol 168(2):550–555
Khosroshahi A, Carruthers MN et al (2013) Rethinking Ormond's disease: „idiopathic“ retroperitoneal fibrosis in the era of IgG4-related disease. Medicine 92(2):82–91
Kukuk S, Kretschmer A, Bruck H, Roth S, Brandt AS. (2014) Retroperitoneale Fibrose: Entwicklung eines Biomarkerprofils zur Diagnostik und Verlaufskontrolle, Urologe A. 2015 Jan;54(1):52–61
Magrey MN, Husni ME et al (2009) Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum 61(5):674–679
Marcolongo R, Tavolini IM et al (2004) Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med 116(3):194–197
Martorana D, Vaglio A et al (2006) Chronic periaortitis and HLA-DRB1*03: another clue to an autoimmune origin. Arthritis Rheum 55(1):126–130
Marzano A, Trapani A et al (2001) Treatment of idiopathic retroperitoneal fibrosis using cyclosporin. Ann Rheum Dis 60(4):427–428
Moroni G, Castellani M et al (2012) The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging 39(10):1635–1642
Mufarrij PW, Stifelman MD (2006) Robotic ureterolysis, retroperitoneal biopsy, and omental wrap for the treatment of ureteral obstruction due to idiopathic retroperitoneal fibrosis. Rev Urol 8(4):226–230
Pelkmans LG, Aarnoudse AJ et al (2012) Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant: Off Publ Eur Dial Transpl Assoc Eur Ren Assoc 27(7):2819–2825
Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN (2009) Nephrogenic systemic fibrosis and its impact on abdominal imaging. Radiographics 29:1565–1574
Scheel PJ Jr, Feeley N (2009) Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation. Medicine (Baltimore) 88(4):202–207
Scheel PJ Jr, Piccini J et al (2007) Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. J Urol 178(1):140–143, discussion 143–144
Scheel PJ Jr, Sozio SM et al (2012) Medical management of retroperitoneal fibrosis. Trans Am Clin Climatol Assoc 123:283–290, discussion 290–281
Stifelman MD, Shah O et al (2008) Minimally invasive management of retroperitoneal fibrosis. Urology 71(2):201–204
Swartz RD (2009) Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment. Am J Kidney Dis 54:546–553
Swartz RD, Lake AM et al (2008) Idiopathic retroperitoneal fibrosis: a role for mycophenolate mofetil. Clin Nephrol 69(4):260–268
Treglia G, Mattoli MV et al (2013) Emerging role of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with retroperitoneal fibrosis: a systematic review. Rheumatol Int 33(3):549–555
Uibu T, Oksa P et al (2004) Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet 363(9419):1422–1426
Vaglio A (2009) Retroperitoneal fibrosis: new insights into clinical presentation and diagnosis. Medicine (Baltimore) 88(4):208–210
Vaglio A, Buzio C (2005) Chronic periaortitis: a spectrum of diseases. Curr Opin Rheumatol 17(1):34–40
Vaglio A, Greco P et al (2006a) Autoimmune aspects of chronic periaortitis. Autoimmun Rev 5(7):458–464
Vaglio A, Salvarani C et al (2006b) Retroperitoneal fibrosis. Lancet 367(9506):241–251
Vaglio A, Palmisano A et al (2011) Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 378(9788):338–346
van Bommel EF, Hendriksz TR et al (2006) Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 144(2):101–106
van Bommel EF, Siemes C et al (2007) Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 49(5):615–625
van Bommel EF, Pelkmans LG et al (2013) Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis. Eur J Int Med 24(5):444–450
Vega J, Goecke H et al (2009) Treatment of idiopathic retroperitoneal fibrosis with colchicine and steroids: a case series. Am J Kidney Dis 53(4):628–637
Warnatz K, Keskin AG et al (2005) Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 64(6):828–833
Zen Y, Onodera M et al (2009) Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol 33(12):1833–1839
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Brandt, A.S., Goedde, D., Kamper, L., Haage, P., Störkel, S., Roth, S. (2015). Retroperitoneale Fibrose (Morbus Ormond). In: Michel, M., Thüroff, J., Janetschek, G., Wirth, M. (eds) Die Urologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-41168-7_112-1
Download citation
DOI: https://doi.org/10.1007/978-3-642-41168-7_112-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-41168-7
eBook Packages: Springer Referenz Medizin
Publish with us
Chapter history
-
Latest
Retroperitoneale Fibrose (Morbus Ormond)- Published:
- 02 February 2022
DOI: https://doi.org/10.1007/978-3-642-41168-7_112-2
-
Original
Retroperitoneale Fibrose (Morbus Ormond)- Published:
- 19 February 2015
DOI: https://doi.org/10.1007/978-3-642-41168-7_112-1